anlotinib + aumolertinib

Anlotinib + aumolertinib is an investigational oral combination therapy consisting of two small molecule tyrosine kinase inhibitors (TKIs): anlotinib, a multitarget antiangiogenic TKI, and aumolertinib, a third-generation epidermal growth factor receptor (EGFR) TKI. This combination is being studied primarily for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations, including those with TP53 co-mutations. Anlotinib inhibits angiogenesis and tumor proliferative signaling by targeting multiple receptors involved in tumor growth and vascularization. Aumolertinib selectively inhibits mutant forms of EGFR, including those resistant to earlier generation TKIs. Preclinical studies show that the combination synergistically suppresses NSCLC cell proliferation by downregulating the PI3K-Akt pathway and modulating apoptosis- and invasion-related proteins. Clinical trials are ongoing to evaluate its efficacy as first-line therapy in advanced NSCLC patients with specific genetic alterations[2][5][6].

Brand names

AmeileElunate

Other names

almonertinib + anlotinib